Zhao Fei-Peng, Liu Xiong, Zhong Zhi-Ming, Lu Juan, Yu Bo-Long, Zeng Fang-Yin, Chen Xiao-Mei, Chen Huai-Hong, Peng Xiao-Hong, Wang Fan, Peng Ying, Li Xiang-Ping
Department of Otolaryngology-Head and Neck Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China ; Department of Otolaryngology, the Third People's Hospital of Chengdu, Chengdu 610031, China.
Department of Otolaryngology-Head and Neck Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
BBA Clin. 2014 Oct 31;2:88-93. doi: 10.1016/j.bbacli.2014.10.003. eCollection 2014 Dec.
Positivity of plasma Epstein-Barr virus (EBV)-DNA or serum virus capsid antigen-specific IgA (VCA-IgA) is a biomarker for the prognosis of nasopharyngeal carcinoma (NPC). The objective of this study was to determine the value of positivity for plasma EBV-DNA and/or VCA-IgA in predicting the survival of patients with NPC.
Plasma EBV-DNA and serum VCA-IgA in 506 NPC patients in this retrospective study were detected by quantitative real time polymerase chain reaction and enzyme-linked immunoabsorbent assay, respectively. The value of positivity for EBV-DNA and/or VCA-IgA in predicting the survival of patients with NPC was analyzed.
Patients with positivity for both EBV-DNA and VCA-IgA had significantly shorter periods of relapse free survival (RFS) and overall survival (OS) than those with positive single measure or negative for both measures, and patients with positive single measure had significantly shorter periods of RFS and OS than those with negative for both. Multivariate analysis indicated that the positivity for EBV-DNA and/or VCA-IgA were significant risk factors for shorter periods of RFS and OS.
These data indicated that positivity for both EBV-DNA and VCA-IgA was a better biomarker for the prognosis of patients with NPC. Our findings may provide new references for clinical practice.
血浆爱泼斯坦-巴尔病毒（EBV）-DNA阳性或血清病毒衣壳抗原特异性IgA（VCA-IgA）是鼻咽癌（NPC）预后的生物标志物。本研究的目的是确定血浆EBV-DNA和/或VCA-IgA阳性在预测NPC患者生存中的价值。
在这项回顾性研究中，分别采用定量实时聚合酶链反应和酶联免疫吸附测定法检测了506例NPC患者的血浆EBV-DNA和血清VCA-IgA。分析了EBV-DNA和/或VCA-IgA阳性在预测NPC患者生存中的价值。
EBV-DNA和VCA-IgA均阳性的患者无复发生存期（RFS）和总生存期（OS）明显短于单项检测阳性或两项检测均阴性的患者，单项检测阳性的患者RFS和OS明显短于两项检测均阴性的患者。多因素分析表明，EBV-DNA和/或VCA-IgA阳性是RFS和OS较短的显著危险因素。
这些数据表明，EBV-DNA和VCA-IgA均阳性是NPC患者预后更好的生物标志物。我们的研究结果可能为临床实践提供新的参考。
